A summary of agents in late-stage development for the prevention and/or treatment of osteoporosis.
Hyrimoz, a High-Concentration Humira Biosimilar, Approved by FDA
Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.
FDA Approves Kevzara for Inflammatory Rheumatic Disease
Kevzara is the first biologic to treat patients with polymyalgia rheumatica (PMR). It is also approved to treat rheumatoid arthritis.
Will the Biosimilar Amjevita Lower Costs?
The real impact may not likely be seen until after July when additional biosimilars referencing Humira are launched.
First Humira Biosimilar is Now Available
Some PBMs will offer Amgen’s Amjevita biosimilar as a preferred product alongside Humira, but CVS Caremark said Humira will remain preferred and Amjevita will be placed on a non-preferred brand tier.
Prime to Cover Biosimilars Alongside Humira
A decision is anticipated in early January about which of the now eight Humira biosimilars will be included.
FDA Approves Fresenius Kabi’s Humira Biosimilar
This is the eighth biosimilar to reference the blockbuster rheumatoid arthritis drug Humira that will launch in 2023.
2 Clarke Drive Cranbury, NJ 08512